ArticleScience advances2020
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 251 papers.
0numbers the graph read from it
0cells of the map it votes in
251citing papers in PubMed
33.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
251 citing papers in PubMed, 392 citations in OpenAlex.
- Nitrile-Based Inhibitors Targeting both SARS-CoV‑2 Main Protease and Human Cathepsin L.ACS medicinal chemistry letters · 2026Article
- Integrated Computational Study Prioritizes Drug-like Para-Flavonoids as Candidate SARS-CoV-2 MCurrent issues in molecular biology · 2026Article
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Tropical psychotria plants are a rich source for peptide inhibitors of human prolyl oligopeptidase.Natural products and bioprospecting · 2026Article
- Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir.ACS pharmacology & translational science · 2026Article
- Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors.Current issues in molecular biology · 2026Article
- Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants.JACS Au · 2026Article
- Mutation-Induced Resistance of SARS-CoV-2 MInternational journal of molecular sciences · 2026Article
- Cooperativity and communication between the active sites of the dimeric SARS-CoV-2 main protease.Science advances · 2026Article
- Machine Learning-Guided Repositioning of a SARS-CoV-2-Targeting Molecular Series as Cruzain Inhibitors.ChemMedChem · 2026Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- A hybrid evolutionary and structural method for AI-guided peptide inhibitor design using AlphaFold and Rosetta.Scientific reports · 2025Article
- Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS-CoV-2.Archiv der Pharmazie · 2025Article
- Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors.Journal of computer-aided molecular design · 2025Review
- Dissecting Interactions between RNA and Coronavirus Nucleocapsid Proteins Using Native Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2025Article
- Therapeutic applications of interface-mimicking peptides for targeting the SARS-CoV-2 NSP12-NSP8 RdRp complex.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- An orally available MNature communications · 2025Article
- Peptidomimetic Phenoxymethyl Ketone Warheads as Potent Dual-Mode Inhibitors against SARS-CoV-2 MJournal of medicinal chemistry · 2025Article
- Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease.Nature communications · 2025Article
191 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
17 authors at 5 institutions in 2 countries.
Michael Dominic SaccoDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.ORCID 0000-0001-5930-7363
Chunlong MaDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.ORCID 0000-0002-5766-8189
Panagiotis LagariasDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens 15771, Greece.
Ang GaoDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Julia Alma TownsendDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
Xiangzhi MengDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Peter DubeDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Xiujun ZhangDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
Yanmei HuDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Naoya KitamuraDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Brett HurstInstitute for Antiviral Research, Utah State University, Logan, UT 84322, USA.ORCID 0000-0003-1025-5878
Bart TarbetInstitute for Antiviral Research, Utah State University, Logan, UT 84322, USA.ORCID 0000-0002-4255-9094
Michael Thomas MartyDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.ORCID 0000-0001-8115-1772
Antonios KolocourisDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens 15771, Greece.
Yan XiangDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Yu ChenDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. junwang@pharmacy.arizona.edu ychen1@usf.edu.ORCID 0000-0002-5115-3600
Jun WangDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA. junwang@pharmacy.arizona.edu ychen1@usf.edu.ORCID 0000-0002-4845-4621
University of Arizona · USThe University of Texas Health Science Center at San Antonio · USUniversity of South Florida · USNational and Kapodistrian University of Athens · GRUtah State University · US
Funding
CHEMISTRY-BIOLOGY INTERFACE TRAINING PROGRAMT32GM008804 · NIGMS · UNIVERSITY OF ARIZONA · PI MONTFORT, WILLIAM R. · 2003 to 2023
$3.9MUnravelling Membrane Protein-Lipid Interactions using Nanodiscs and Mass SpectrometryR35GM128624 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Michael T Marty · 2018 to 2026
$3.6MNovel Translational Control Mechanisms in Host Range Restriction of PoxvirusR01AI151638 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI YAN XIANG · 2020 to 2026
$3.4MDrug target validation of the enterovirus D68 2A proteaseR01AI157046 · NIAID · UNIVERSITY OF ARIZONA · PI WANG, JUN · 2020 to 2024
$3.4MHigh Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A ProteasesR01AI147325 · NIAID · UNIVERSITY OF ARIZONA · PI WANG, JUN · 2019 to 2022
$1.7MNIAID NIH HHS R01 AI147325NIAID NIH HHS R01 AI151638NIAID NIH HHS R01 AI157046NIGMS NIH HHS R35 GM128624NIGMS NIH HHS T32 GM008804NIH HHS AI147325NIH HHS AI157046
Abstract
The main protease (M
Indexed as
Drug DesignMolecular Dynamics SimulationAnimalsCaco-2 CellsCathepsin LCell LineCell Line, TumorChlorocebus aethiopsCoronavirus 3C ProteasesCrystallography, X-RayDogsHumansKineticsMadin Darby Canine Kidney CellsModels, ChemicalMolecular StructureCathepsin LCoronavirus 3C ProteasesProtease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.